retatrutide phase 2 trial obesity nejm 2023 The that put “24%” on the map retatrutide phase 2 nejm 2023

Presented for research literature review only Iliceto S (1998)

Disclaimer: Compounded medications are NOT FDA-approved and differ from brand names

Regulatory status will remain contingent on new data and prevailing evidence standards, as well as the absence of approved therapeutic uses to date

Earlier this month, (June 2025), Novo inked a deal worth up to $815 million with Deep Apple Therapeutics, a South San Francisco-based company specializing in small-molecule drug discovery to discover, develop, and commercialize oral small-molecule therapeutics directed at a non-incretin G protein-coupled receptors (GPCR) target for cardiometabolic diseases, including obesity, in a deal worth up to $812 million

Caroline Apovian, an obesity medicine specialist Massachusetts was among just 13 states whose Medicaid programs covered GLP-1s for weight loss at the beginning of 2026, according to the research organization KFF